Eloxx Pharmaceuticals, Inc. (ELOX)
NASDAQ: ELOX · Real-Time Price · USD
13.20
0.00 (0.00%)
Oct 30, 2026, 9:55 AM EDT - Market open
Eloxx Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
10
Market Cap
53.28M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 6.36M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Jun 30, 2016 | 75.00K | - | - |
| Dec 31, 2015 | - | - | - |
| Jun 30, 2015 | 75.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Jun 30, 2014 | 100.00K | - | - |
| Jun 30, 2013 | - | - | - |
| Jun 30, 2012 | 200.00K | - | - |
| Jun 30, 2011 | - | - | - |
| Jun 30, 2010 | 140.00K | -135.00K | -49.09% |
| Jun 30, 2009 | 275.00K | -181.67K | -39.78% |
| Jun 30, 2008 | 456.67K | 156.67K | 52.22% |
| Jun 30, 2007 | 300.00K | 233.33K | 350.00% |
| Jun 30, 2006 | 66.67K | -58.33K | -46.67% |
| Jun 30, 2005 | 125.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xilio Therapeutics | 64.09M |
| Werewolf Therapeutics | 21.00M |
| Alps Group | 3.74M |
| Connect Biopharma Holdings | 2.95M |
| Hyperion DeFi | 1.40M |
| Clene | 197.00K |
| iBio, Inc. | 100.00K |
ELOX News
- 1 day ago - Eloxx Pharmaceuticals announces FDA clearance of IND application for exaluren - TheFly
- 1 day ago - Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD - PRNewsWire
- 2 days ago - Eloxx Pharmaceuticals price target lowered to $40 from $43 at Guggenheim - TheFly
- 10 days ago - Eloxx Pharmaceuticals appoints T.R. Srinivas as CMO - TheFly
- 10 days ago - Eloxx Pharmaceuticals finalizes Phase 2 EXPRESS study design - TheFly
- 10 days ago - Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D. - PRNewsWire
- 10 days ago - Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors - PRNewsWire
- 15 days ago - Eloxx Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald - TheFly